XTAE
EMTC-M
Market cap6mUSD
Feb 17, Last price
22.20ILS
Name
Elbit Medical Technologies Ltd
Chart & Performance
P/E
8.10
P/S
—
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
-17.09%
Rev. gr., 5y
112.53%
Revenues
0k
-100.00%
Net income
827k
P
CFO
-542k
L-8.14%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Elbit Medical Technologies Ltd functions as an investment holding company, with its core activities centered on the innovation, production, and global commercialization of therapeutic medical devices. The company maintains a presence across the United States, Europe, and other international territories. A key initiative involves the advancement of a magnetic resonance imaging (MRI) guided focused ultrasound treatment system, designed to tackle a range of medical challenges, including various cancers (oncology), gynecological conditions, neurological disorders, and tumors. Additionally, Elbit Medical Technologies is engaged in the extensive study and creation of medical products leveraging stem cells, predominantly sourced from umbilical cord blood. These stem cell applications are critical for bone marrow transplants in individuals affected by leukemia, lymphatic system cancers, non-malignant hematological diseases, and inherited metabolic genetic conditions. Headquartered in Petah Tikva, Israel, Elbit Medical Technologies Ltd is a wholly-owned subsidiary of Exigent Management Ltd.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||